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Abstract
Introduction and Objectives: The coronavirus disease 2019 (COVID-19) pandemic has resulted in patients experiencing
symptoms that include neurological dysfunction. As many viral infections are associated with neuropathy, the aim of the study is to
characterize the incidence and severity of neuropathic pain in patients with COVID-19.
Methods: A cohort study will be conducted in adult ($18 years) patients who were tested for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) at Washington University/Barnes-Jewish Hospital. Participants who are deceased, with incomplete test
results, orwhocannot be contactedwill be excluded.Approximately 1320participantswill be recruited in a 1:2 ratio of thosewith apositive-
to-negative SARS-CoV-2 test result. Each participant will be invited to complete a survey to assess their symptoms related to neuropathy,
30 to 90days after their initial SARS-CoV-2 test. Survey responses, demographics, andclinical data from the electronic health recordwill be
used for analysis. The primary outcome is the incidence of new symptoms of neuropathic pain. The self-reported DN4 and Neuropathic
Pain Symptom Inventory questionnaires (Appendix 1, http://links.lww.com/PR9/A103) will be used for neuropathic pain screening and
severity assessment, respectively. Exploratory analyses will be performed to investigate other potential clinical endpoints and trends.
Results/Conclusion: Similar to previous coronavirus infections, an increased incidence of new-onset neuropathic pain after COVID-19
disease is expected, along with an increase in the severity experienced by patients with COVID-19 with pre-existing chronic pain.
ComprehensiveunderstandingofhowCOVID-19affects thenervoussystemcanprovideabetter framework formanagingpain in thisdisease.
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1. Introduction
December 2019 witnessed the identification of a novel corona-
virus, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), in Wuhan, China, which has escalated to a global
pandemic with a 2.6% mortality rate. As of November 1, 2020,
more than 47 million confirmed cases have been reported
worldwide.22 Coronavirus disease 2019 (COVID-19) syndrome is
the disease caused by SARS-CoV-2 infection, with common
symptoms including cough, headache, fever, dyspnea, and
fatigue to more severe sequelae such as severe respiratory
distress, acute cardiac injury, thrombosis, and death.8
Severe acute respiratory syndrome coronavirus 2 is the
seventh identified coronavirus capable of infecting humans24
and shares many molecular and clinical similarities to the other
betacoronaviruses, such as MERS-CoV and SARS-CoV,
which caused Middle East respiratory syndrome (MERS) and
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severe acute respiratory syndrome (SARS), respectively.16,23,25
Emerging reports of changes to smell and taste perception
(anosmia, hyposmia, ageusia, or dysgeusia)13,14 in patients with
COVID-19, even before or without the manifestation of other
symptoms related to SARS-CoV-2 infection,6 suggest a possible
sensory dysfunction in the course of this disease.
Both MERS and SARS, along with other viruses such HIV,
varicella zoster virus, and hepatitis C, have been associated
with peripheral neuropathies.5,9–11,15,19,21 There are several
published case series, small-scale retrospective observational
studies, and anecdotal evidence of neuropathic pain and other
neurological symptoms in patients with confirmed COVID-
19.12,14,17,20 However, it is unclear whether SARS-CoV-2
infection and subsequent COVID-19 disease are associated
with an increased risk of painful peripheral neuropathy or
cranial nerve dysfunction. Timely and accurate diagnosis of
neuropathy and neuropathic pain can allow early intervention
and possible mitigation of long-term symptoms and quality of
life impairment. The goal of this cohort study will be to
determine the incidence and characteristics of neuropathic
pain symptoms and cranial nerve dysfunction associated with
COVID-19.
2. Methods
2.1. Study design and participants
The protocol for this study was approved by the Institutional
Review Board (IRB) at the Washington University School of
Medicine in St. Louis (IRB# 202004043).Wewill conduct a cohort
study of individuals who were tested for SARS-CoV-2, using a
reverse transcriptase polymerase chain reaction (RT-PCR)
testing. Participants will be divided into 2 cohorts based on either
a positive (CV191) or negative (CV192) result on their SARS-
CoV-2 RT-PCR test.
Participants will be recruited from 3 sites that were part of
the same academic medical center in Missouri, USA, as
identified through the Epic electronic health record system
(Verona, WI). The study sites include the Barnes-Jewish
Hospital, the Washington University School of Medicine, and
the St. Louis Children’s Hospital. All participants will be at least
18 years old and would have presented for SARS-CoV-2
testing for any indication (eg, symptomatic presentation,
possible exposure, or perioperative screening) to one of the
clinics or hospitals associated with the study sites on or after
March 16, 2020. Participants will be excluded if they were
younger than 18 years old, known to be deceased at the time
of sending study surveys, or do not have available RT-PCR test
results or contact information on their patient record. Study
participants will be provided with a consent information
sheet along with the study survey and will indicate their
consent by completing the web-based or mail-based survey
(Appendix 1, available at http://links.lww.com/PR9/A103).
2.2. Data collection
Demographic and clinical data including age, sex, race,
ethnicity, marital status, medical history, tobacco and alcohol
use, comorbidities, medications, associated symptoms (eg,
fever, cough, pneumonia, anosmia, or ageusia), available
influenza test results, and COVID-19–related hospitalization
details (if hospitalized) will be extracted from the patient record.
COVID-19 disease severity will be assessed based on the level
of care (hospital admission and intensive care unit admission),
length of hospitalization, time to intubation from disease onset, if
known, and mechanical ventilation requirement and settings.
An email with a link to a secure web-based survey on the
REDCap platform7 will be sent to all participants approxi-
mately 30 to 90 days from the time of their SARS-CoV-2 RT-
PCR test results. As a follow-up, participants who do not
respond to 2 online survey invitations may be contacted
through telephone and invited to participate in the web-based
survey or provide a mailing address to send a paper copy of
the survey, along with a consent form, by postal mail with a
prepaid return envelope.
The survey includes questions on patient-reported symptoms
of peripheral neuropathy or cranial nerve dysfunction at 3 time
points: at the time of initial symptoms (or SARS-CoV-2 testing, if
asymptomatic), 1 to 2 weeks after symptom manifestation or
testing, and at the time of questionnaire completion (Appendix 1,
available at http://links.lww.com/PR9/A103). Data will also be
collected on previous chronic pain or neuropathic conditions. For
those reporting symptoms of neuropathy or nerve dysfunction, a
branching logic will be used to (1) assess the anatomical
distribution of pain or neuropathy on a body diagram, (2)
complete the 7-item self-report DN4 neuropathic pain screening
questionnaire,1 and (3) complete the Neuropathic Pain Symptom
Inventory (NPSI).2
2.3. Outcomes
The primary outcome of this study is the incidence of new
symptoms of peripheral neuropathy, between the CV191 and
CV192 patient cohorts. DN4 and NPSI scores will be used to
screen for neuropathic pain and determining its severity, re-
spectively (Appendix 1, available at http://links.lww.com/PR9/
A103). Additional outcomes include symptoms of motor neurop-
athy and cranial nerve I to XII dysfunction and change in severity of
pre-existing chronic pain or neuropathy. The variety of symptoms
associated with new or worsened neuropathy will be qualitatively
compared between the 2 cohorts.
2.4. Statistical analysis
Continuous data will be expressed as mean (standard deviation)
or median (interquartile range) values, as appropriate, and
categorical variables will be expressed as frequencies, n (%).
Differences in symptoms and baseline characteristics between
the 2 cohorts will be reported using effect size metrics and 95%
confidence intervals. Demographics of survey responders and
nonresponders will be compared to determine the risk of
responder bias. The overall incidence of new symptoms of
peripheral neuropathy or cranial nerve dysfunction, based on the
survey, will be compared between the 2 cohorts using the Fisher
exact test. Continuous data will be assessed for normality using
the Shapiro–Wilk test, and nonparametric and parametric data
will be analyzed using a Mann–Whitney U test or two-sample t
test, respectively, where applicable.
Multivariable logistic regression with composite outcome of
new peripheral neuropathy, adjusted for demographic factors
and comorbidities, will be performed. Bivariate analyses of clinical
characteristics will be performed to identify associations with an
incidence of new peripheral neuropathy, which will therefore be
included in the multivariable logistic regression model. Assuming
a 1% incidence of new neuropathic pain in the CV192 cohort, to
detect an incidence of 3.5% or more of peripheral neuropathy in
the CV191 cohort with 80% power and a 5 0.05, the study will
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require 1320 participants overall in a 1:2 ratio of CV191 to
CV192 subjects (ie, 440 CV191 and 880 CV192).
As a secondary outcome, the incidence of neuropathic pain
based on a DN4 score $4 will be compared between the 2
cohorts using the x2 test. Finally, a t test will be used to compare
the severity of neuropathy from the total NPSI score between the
CV191 and CV192 cohorts.
As the study cohorts are defined by the SARS-CoV-2 RT-PCR
test result, and not an initial clinical presentation of COVID-19
disease, 2 sensitivity analyses will be conducted based on (1)
patients’ self-reported symptoms as a reason for testing and (2)
clinical diagnoses of COVID-19 in the Epic electronic health
record, pending complete data availability.
All statistical analyses will be performed using R software
version 4.0.1. A P value of ,0.05 is the threshold for statistical
significance for all analyses.
3. Discussion
This cohort study aims to characterize neuropathic pain
symptoms in patients with SARS-CoV-2 infection. Study
participants in the CV192 cohort will serve as a comparator to
elucidate the differences in severity and incidence of peripheral
neuropathy among patients with and without a positive SARS-
CoV-2 RT-PCR test. The CV192 cohort will be selected among
patients from the same geographical area and are tested for
SARS-CoV-2, to account for similar circumstances that could
have resulted in a new onset of neuropathy symptoms.
Neurological symptoms will be compared between the cohorts
and then discussed in the context of current literature on
neuropathic pain after other viral infections.
Sensory and motor peripheral neuropathies after MERS and
SARS infections have been extensively reported.11,21 In both
cases, the onset of neurological symptoms occurred 2 to 3weeks
after the initial viral infection and involved varying complications,
such as limb weakness, hyporeflexia, and hypoesthesia in 2 or all
4 limbs. In our study, a time frame of 1 to 3 months was selected
to account for the possible delay in symptom manifestation after
the initial acute nerve insult. In a systematic review of patients with
COVID-19 who were admitted to a Spanish hospital, 57.4% of
patients experienced neurological symptoms17; this prevalence is
similar to a retrospective study in Wuhan, China, where 36.4% of
the study population experienced neurological symptoms such
as dizziness (16.8%), headache (13.1%), impaired conscious-
ness (7.5%), skeletal muscle injury (10.1%), and peripheral
nervous system symptoms, such as sensory impairment and
nerve pain (8.9%).14 In the study by Romero-Sanchez et al.
(2020), viral RNA could not be detected in any of the
cerebrospinal fluid samples. Although the exact mechanism for
howSARS-CoV-2 affects the peripheral nervous system is not yet
known, Shiers et al. 18 found that a subset of human dorsal root
ganglion neurons were nociceptors that expressed the mRNA of
the SARS-CoV-2 receptor, ACE2. They suggested that the
nociceptors could form free nerve endings on the skin and luminal
organs, serving as a route for SARS-CoV-2 infection. Results
from our study will be discussed and compared in the context of
the published literature.
The study is limited by the lack of complete neurological
examinations by an independent neurologist for each participant.
For example, symptoms of blurred vision, diplopia, or vision loss
could be due to cranial nerves II, III, IV, and/or VI; however,
without an in-person neurological examination it is difficult to
further localize the ocular lesion. Clinical signs of peripheral
neuropathy, muscle pain, and cranial nerve dysfunction will be
self-reported without necessarily having an accompanying
clinical diagnosis on their medical record. However, a strength
of this study is the use of DN4 and NPSI scores as 2 individually
validated questionnaires to screen for neuropathic pain.1,2 There
is a potential risk of recall bias because some parts of the
questionnaire ask participants about their symptoms at the time
of testing or symptom onset. However, as the time frame for recall
is relatively short and applied to all study participants, this
potential for bias is likely to be low and balanced between the 2
study cohorts. Finally, the possibility of false negatives from RT-
PCR testing for SARS-CoV-2 may mean that some of the
participants in the CV192 cohort should have been in the CV191
cohort. This potential confounder in our study may affect the
findings and make it more difficult to detect a true difference
between the 2 cohorts. The early detection of viral-induced
neuropathies is important to treat and prevent more severe
complications after infection and to aid in rational drug design
approaches. The delay in reporting peripheral neuropathy in
people with HIV led to millions being underdiagnosed or
undertreated during the AIDS epidemic in the 1980s.3,4 Should
there be a significant increase in neuropathy after SARS-CoV-2
infection, our findings may add to the literature supporting a role
for the nervous system in the pathogenesis of COVID-19 disease.
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